Оребритон

Оребритон (Ticagrelor) is an oral antiplatelet medication used to reduce the risk of blood clots in patients with heart conditions. It belongs to the P2Y12 inhibitor class and is prescribed to prevent strokes and heart attacks. This EU-manufactured generic offers a reliable option for cardiovascular support.

Ticagrelor is primarily used to prevent blood clots in people with acute coronary syndromes or a history of heart attack. It works by blocking platelets from sticking together, reducing the risk of blockages in arteries. Doctors may prescribe it alongside aspirin for added protection. Patients often ask, 'What is Ticagrelor used for?'—it’s designed for long-term cardiovascular risk reduction.

Ticagrelor helps maintain healthy blood flow by preventing platelets from clumping. Users may notice improved circulation and reduced chest discomfort linked to heart conditions. Some report mild effects like shortness of breath or dizziness, which are typically temporary. It does not cure underlying heart disease but supports ongoing management.

Ticagrelor should be taken exactly as prescribed, usually twice daily with or without food. Avoid sudden discontinuation unless directed by a healthcare provider, as this may increase clot risk. Patients with bleeding disorders or severe liver issues should use caution. Always inform your doctor about all medications and conditions before starting Ticagrelor.

Ticagrelor can interact with blood thinners, NSAIDs, and certain antidepressants, increasing bleeding risk. Grapefruit juice may affect how the drug works, so moderation is advised. Strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) can alter Ticagrelor levels. Alcohol use should be limited due to potential side effects like dizziness.